Evidence map›Paper›PMID 32420072›Full record

ArticleTranslational lung cancer research2020

Hormone receptor expression correlates with EGFR gene mutation in lung cancer in patients with simultaneous primary breast cancer.

Zhihuang Hu, Xuan Zou, Shanshan Qin, Yuan Li, Huijie Wang, Hui Yu, Si Sun, Xianghua Wu, Jialei Wang, Jianhua Chang

Open access · diamondAbstract read
In one paragraph

Article in Translational lung cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The value of [BMC medical imaging · 2025
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Zhihuang HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xuan ZouDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Shanshan QinDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yuan LiInstitute of Thoracic Oncology, Fudan University, Shanghai 200032, China.
Huijie WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Hui YuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Si SunDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xianghua WuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jialei WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jianhua ChangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Shanghai Medical College of Fudan University · CNFudan University Shanghai Cancer Center · CNFudan University · CNJinshan Hospital of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe coexistence of double primaries of lung cancer (LC) and breast cancer (BC) are not uncommon in women, but there has been limited research conducted of their molecular association. To decipher the internal pathogenesis of LC in patients with concurrent BC and LC, this study explored the clinical factors and relationship between hormone receptor (HR) expression and epidermal growth factor receptor (EGFR) gene mutation.

methodsThe clinicopathological characteristics of 400 female patients clinically diagnosed with double primary LC and BC at Fudan University Shanghai Cancer Center were collected. Pathological discrimination was performed to further confirm the double primaries in patients with available tissues. LC samples were then examined to detect EGFR gene mutation status by PCR-based assays and HR expression by immunohistochemistry (IHC). As a control cohort, the characteristics of 114 consecutive patients with LC only were compared with the double-primary patient group.

resultsA total of 169 patients were pathologically confirmed with simultaneous LC and BC between January 2010 and October 2018. The dominant LC subtype was adenocarcinoma (ADC) (95.1%), and invasive ductal carcinoma (IDC) was the main BC subtype (71.0%). Synchronous and metachronous double primary BC-LC cases accounted for 39.1% and 60.9% of the patients, respectively. The absence of family cancer history was associated with a shorter interval between the two primary cancer diagnoses. Among 64 patients with EGFR mutations, 34.4% had HR-positive LC tissue, compared with 0/24 (0%) of those with EGFR wild-type LC (P<0.001). All of the patients with positive HR expression harbored an activating EGFR mutation (n=22); however, no correlation was observed in the control cohort.

conclusionsDouble primary BC-LC patients have distinctive clinicopathological features compared to those with LC only. The expression of HRs is significantly correlated with EGFR mutation status of LC tissues.

Indexed as

breast cancer (BC)double primaryepidermal growth factor receptor (EGFR)estrogen receptorLung cancer (LC)progesterone receptor

Identifiers

PMID32420072
PMCPMC7225161
OpenAlexW3019007675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.